Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
    52.
    发明授权
    Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies 有权
    抗Von Willebrand因子切割蛋白酶(ADAMTS13)抗体的诊断测定

    公开(公告)号:US07943326B2

    公开(公告)日:2011-05-17

    申请号:US12829872

    申请日:2010-07-02

    IPC分类号: G01N33/53

    CPC分类号: G01N33/86 C12Q1/56

    摘要: This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.

    摘要翻译: 本发明涉及一种用于测定样品中抗血管性血友病因子切割蛋白酶(“vWF-cp”)抗体的测定系统的试剂盒。 该试剂盒包含固定在固相上的vWF-cp和/或vWF-片段。 该试剂盒可用于测定来自患者的抗vWF-cp抗体的方法,用于诊断与抗vWF-cp抗体发生相关的病症,以及各种形式的血栓性微血管病变的分化。

    HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX
    56.
    发明申请
    HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX 有权
    高度磷酸化和硫化重组因子IX

    公开(公告)号:US20080176287A1

    公开(公告)日:2008-07-24

    申请号:US12058473

    申请日:2008-03-28

    IPC分类号: C12P21/04

    摘要: The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.

    摘要翻译: 本发明涉及纯化的重组凝血因子IX(rFIX)制剂,其中至少25%的制剂中的rFIX被完全磷酸化和硫酸化,表达产生所述制备的rFIX的细胞培养物,用于治疗的药物组合物 包括所述制剂的出血病症和治疗出血性疾病的方法,包括将所述制剂给予需要的患者的步骤。

    Factor IXa specific antibodies displaying factor VIIIa like activity
    57.
    发明授权
    Factor IXa specific antibodies displaying factor VIIIa like activity 有权
    显示因子VIIIa的活性因子IXa特异性抗体

    公开(公告)号:US07297336B2

    公开(公告)日:2007-11-20

    申请号:US10661366

    申请日:2003-09-12

    IPC分类号: A61K39/395

    摘要: Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating patients afflicted with blood coagulation with such ligands, and a nucleic acid that encodes, or a cell that expresses such ligands, are provided.

    摘要翻译: 配体,例如可以结合因子IX /因子IXa并增加因子IXa(FIXa)的促凝血活性的抗体,含有这种配体的药物组合物,用这种配体治疗患有凝血的患者的方法,以及编码或 提供表达这种配体的细胞。

    HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX
    58.
    发明申请
    HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX 有权
    高度磷酸化和硫化重组因子IX

    公开(公告)号:US20070244036A1

    公开(公告)日:2007-10-18

    申请号:US11683362

    申请日:2007-03-07

    IPC分类号: A61K38/36 C12N5/08

    摘要: The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.

    摘要翻译: 本发明涉及纯化的重组凝血因子IX(rFIX)制剂,其中至少25%的制剂中的rFIX被完全磷酸化和硫酸化,表达产生所述制备的rFIX的细胞培养物,用于治疗的药物组合物 包括所述制剂的出血病症和治疗出血性疾病的方法,包括将所述制剂给予需要的患者的步骤。